Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Corvus Pharmaceuticals, Inc.CRVS · Entity 4839 | Chief Financial Officer | December 04, 2025 | December 08, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Corvus Pharmaceuticals, Inc.
Report date December 04, 2025 · Filed December 08, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.81 · Expires 2035-12-04 | Direct | 400,000 |
Reported balance
After 2025-12-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-12-04 · Grant · Acquired 400,000 · Balance 400,000 F1: The underlying shares subject to the option vest and become exercisable as to 1/36th of the shares subject to the option in successive, equal monthly installments measured from December 4, 2025, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The underlying shares subject to the option vest and become exercisable as to 1/36th of the shares subject to the option in successive, equal monthly installments measured from December 4, 2025, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 04, 2025 Filed Dec 8, 2025 16:21 UTC | Corvus Pharmaceuticals, Inc. CRVS · Entity 4839 | GrantStock Option (Right to Buy) · Derivative | 400,000 | $0.00 Strike: $8.81 | $0.00 |
DisclosureSEC source: 0001610717-25-000409 · form4.xml · derivative · entry 1 LEA LEIV · CIK 0000939012 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2035-12-04 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 1/36th of the shares subject to the option in successive, equal monthly installments measured from December 4, 2025, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| December 20, 2024 Filed Dec 23, 2024 16:39 UTC | Corvus Pharmaceuticals, Inc. CRVS · Entity 4839 | GrantStock Option (Right to Buy) · Derivative | 300,000 | $0.00 Strike: $4.99 | $0.00 |
DisclosureSEC source: 0001610717-24-000551 · form4.xml · derivative · entry 1 LEA LEIV · CIK 0000939012 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2034-12-20 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 1/36th of the shares subject to the option in successive, equal monthly installments measured from December 20, 2024, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| December 06, 2023 Filed Dec 8, 2023 16:08 UTC | Corvus Pharmaceuticals, Inc. CRVS · Entity 4839 | GrantStock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $1.64 | $0.00 |
DisclosureSEC source: 0001610717-23-000394 · form4.xml · derivative · entry 1 LEA LEIV · CIK 0000939012 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2033-12-06 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 1/36th of the shares subject to the option in successive, equal monthly installments measured from December 6, 2023, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| December 14, 2022 Filed Dec 15, 2022 16:33 UTC | Corvus Pharmaceuticals, Inc. CRVS · Entity 4839 | PurchaseCommon Stock | 4,000 | $0.84 | $3,364.00 |
DisclosureSEC source: 0001567619-22-021651 · doc1.xml · nonDerivative · entry 2 LEA LEIV · CIK 0000939012 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By IRA Disclosed balance after: 133,238 F2 · ownership.nature: These shares are held by Leiv Lea IRA Contributory. Read SEC document |
| December 13, 2022 Filed Dec 15, 2022 16:33 UTC | Corvus Pharmaceuticals, Inc. CRVS · Entity 4839 | PurchaseCommon Stock | 30,000 | $0.74 | $22,275.00 |
DisclosureSEC source: 0001567619-22-021651 · doc1.xml · nonDerivative · entry 1 LEA LEIV · CIK 0000939012 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By IRA Disclosed balance after: 129,238 F1 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.7255 to $0.7806, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the SEC full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: These shares are held by Leiv Lea IRA Contributory. Read SEC document |
| August 11, 2022 Filed Aug 15, 2022 18:49 UTC | Corvus Pharmaceuticals, Inc. CRVS · Entity 4839 | GrantStock Option (Right to Buy) · Derivative | 160,000 | $0.00 Strike: $0.97 | $0.00 |
DisclosureSEC source: 0001567619-22-016299 · doc1.xml · derivative · entry 1 LEA LEIV · CIK 0000939012 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,000 Underlying: Common Stock · 160,000 shares Expires 2032-08-11 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to one-forty eighth (1/48th) of the shares subject to the option in successive, equal monthly installments measured from August 11, 2022, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| March 17, 2022 Filed Mar 17, 2022 19:10 UTC | Corvus Pharmaceuticals, Inc. CRVS · Entity 4839 | PurchaseCommon Stock | 13,878 | $1.65 | $22,898.70 |
DisclosureSEC source: 0001567619-22-007173 · doc1.xml · nonDerivative · entry 2 LEA LEIV · CIK 0000939012 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By IRA Disclosed balance after: 99,238 F3 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.62 to $1.66 inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the SEC full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: These shares are held by Leiv Lea IRA Contributory. Read SEC document |
| March 16, 2022 Filed Mar 17, 2022 19:10 UTC | Corvus Pharmaceuticals, Inc. CRVS · Entity 4839 | PurchaseCommon Stock | 35,160 | $1.54 | $54,146.40 |
DisclosureSEC source: 0001567619-22-007173 · doc1.xml · nonDerivative · entry 1 LEA LEIV · CIK 0000939012 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By IRA Disclosed balance after: 85,360 F1 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.45 to $1.60 inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the SEC full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: These shares are held by Leiv Lea IRA Contributory. Read SEC document |
| September 09, 2021 Filed Sep 13, 2021 16:59 UTC | Corvus Pharmaceuticals, Inc. CRVS · Entity 4839 | GrantStock Option (Right to Buy) · Derivative | 160,000 | $0.00 Strike: $2.60 | $0.00 |
DisclosureSEC source: 0001567619-21-017014 · doc1.xml · derivative · entry 1 LEA LEIV · CIK 0000939012 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,000 Underlying: Common Stock · 160,000 shares Expires 2031-09-09 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to one-forty eighth (1/48th) of the shares subject to the option in successive, equal monthly installments measured from September 9, 2021, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| December 16, 2020 Filed Dec 17, 2020 16:17 UTC | Corvus Pharmaceuticals, Inc. CRVS · Entity 4839 | GrantStock Option (Right to Buy) · Derivative | 160,000 | $0.00 Strike: $4.01 | $0.00 |
DisclosureSEC source: 0001567619-20-021268 · doc1.xml · derivative · entry 1 LEA LEIV · CIK 0000939012 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,000 Underlying: Common Stock · 160,000 shares Expires 2030-12-16 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to one-forty eighth (1/48th) of the shares subject to the option in successive, equal monthly installments measured from December 16, 2020, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| December 12, 2019 Filed Dec 16, 2019 16:13 UTC | Corvus Pharmaceuticals, Inc. CRVS · Entity 4839 | GrantStock Option (Right to Buy) · Derivative | 160,000 | $0.00 Strike: $3.54 | $0.00 |
DisclosureSEC source: 0001567619-19-023143 · doc1.xml · derivative · entry 1 LEA LEIV · CIK 0000939012 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,000 Underlying: Common Stock · 160,000 shares Expires 2029-12-12 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to one-forty eighth (1/48th) of the shares subject to the option in successive, equal monthly installments measured from December 12, 2019, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| June 07, 2019 Filed Jun 10, 2019 16:12 UTC | Corvus Pharmaceuticals, Inc. CRVS · Entity 4839 | PurchaseCommon Stock, $0.0001 par value | 10,000 | $3.38 | $33,800.00 |
DisclosureSEC source: 0001567619-19-013152 · doc1.xml · nonDerivative · entry 2 LEA LEIV · CIK 0000939012 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By IRA Disclosed balance after: 50,200 F3 · price: The price reported in Column 4 is a weighted price. These Shares were purchased in multiple transactions at prices ranging from $3.29 to $3.40 inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the SEC full information regarding the Shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: These shares are held by Leiv Lea IRA Contributory. Read SEC document |
| June 06, 2019 Filed Jun 10, 2019 16:12 UTC | Corvus Pharmaceuticals, Inc. CRVS · Entity 4839 | PurchaseCommon Stock, $0.0001 par value | 15,500 | $3.56 | $55,180.00 |
DisclosureSEC source: 0001567619-19-013152 · doc1.xml · nonDerivative · entry 1 LEA LEIV · CIK 0000939012 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By IRA Disclosed balance after: 40,200 F1 · price: The price reported in Column 4 is a weighted price. These Shares were purchased in multiple transactions at prices ranging from $3.50 to $3.64 inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the SEC full information regarding the Shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: These shares are held by Leiv Lea IRA Contributory. Read SEC document |
| December 21, 2018 Filed Dec 27, 2018 16:08 UTC | Corvus Pharmaceuticals, Inc. CRVS · Entity 4839 | PurchaseCommon Stock, $0.0001 par value | 24,700 | $4.15 | $102,408.67 |
DisclosureSEC source: 0000899243-18-031810 · doc4.xml · nonDerivative · entry 1 LEA LEIV · CIK 0000939012 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By IRA Disclosed balance after: 24,700 F1 · price: The price reported in Column 4 is a weighted price. These Shares were purchased in multiple transactions at prices ranging from $4.13 to $4.17 inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the SEC full information regarding the Shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: These shares are held by Leiv Lea IRA Contributory. Read SEC document |
| December 12, 2018 Filed Dec 14, 2018 16:06 UTC | Corvus Pharmaceuticals, Inc. CRVS · Entity 4839 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $5.94 | $0.00 |
DisclosureSEC source: 0000899243-18-031057 · doc4.xml · derivative · entry 2 LEA LEIV · CIK 0000939012 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2028-12-12 F3 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to one-forty eighth (1/48th) of the shares subject to the option in successive, equal monthly installments measured from December 12, 2018, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| December 13, 2017 Filed Dec 15, 2017 16:08 UTC | Corvus Pharmaceuticals, Inc. CRVS · Entity 4839 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $10.60 | $0.00 |
DisclosureSEC source: 0000899243-17-028853 · doc4.xml · derivative · entry 2 LEA LEIV · CIK 0000939012 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2027-12-13 F3 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to one-forty eighth (1/48th) of the shares subject to the option in successive, equal monthly installments measured from December 13, 2017, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| December 07, 2016 Filed Dec 8, 2016 19:03 UTC | Corvus Pharmaceuticals, Inc. CRVS · Entity 4839 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $16.37 | $0.00 |
DisclosureSEC source: 0001140361-16-089146 · doc1.xml · derivative · entry 1 LEA LEIV · CIK 0000939012 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2026-12-07 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to one-forty-eighth (1/48th) of the shares subject to the option in successive, equal monthly installments measured from December 7, 2016, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| August 25, 2016 Filed Feb 10, 2017 16:18 UTC | Corvus Pharmaceuticals, Inc. CRVS · Entity 4839 | GiftCommon Stock, $0.0001 par value | 2,047 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-003462 · doc5.xml · nonDerivative · entry 2 LEA LEIV · CIK 0000939012 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 149,206 F1 · balance_after: A portion of these shares is subject to a right of repurchase held by the Issuer. F2 · ownership.nature: These shares are held by Leiv Lea and Deborah Karlson, Trustees of the Karlson Lea Family Trust UTA dated February 11, 1998 (the "Karlson Lea Trust"). Mr. Lea has shared voting, investment and dispositive power over the shares held by the Karlson Lea Trust. Read SEC document |
| August 25, 2016 Filed Feb 10, 2017 16:18 UTC | Corvus Pharmaceuticals, Inc. CRVS · Entity 4839 | GiftCommon Stock, $0.0001 par value | 48,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-003462 · doc5.xml · nonDerivative · entry 1 LEA LEIV · CIK 0000939012 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 151,253 F1 · balance_after: A portion of these shares is subject to a right of repurchase held by the Issuer. F2 · ownership.nature: These shares are held by Leiv Lea and Deborah Karlson, Trustees of the Karlson Lea Family Trust UTA dated February 11, 1998 (the "Karlson Lea Trust"). Mr. Lea has shared voting, investment and dispositive power over the shares held by the Karlson Lea Trust. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.